drugset / Trial / NCT00006047
Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide
Phase 1
Completed
44 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Astex Pharmaceuticals, Inc. · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of nitrocamptothecin plus etoposide in treating patients who have advanced solid tumors.
Timeline
- Start
- 2000-06
- Primary completion
- 2003-02
- Completion
- 2003-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rubitecan | Unknown | — | Oral |
| Background | Etoposide | Small molecule | — | Oral |